Image

Cerebello-motor Neuromodulation After Stroke. CERSTIM.

Cerebello-motor Neuromodulation After Stroke. CERSTIM.

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The CERSTIM study is a physiopatholgical study investigating transcranial alternating current stimulation in stroke patients in the cerebello-motor loop.

The design is a cross over design testing two frequencies in the gamma band and one placebo.

We will use behavioural data, functional MRI, and Electroencephalography to disentangle the effect of tACS and its frequency.

Healthy participants will be also recruited.

Description

Neuromodulation, by the means of Non-Invasive Brain Stimulation techniques, is a promising method to enhance motor recovery of the upper limb following a stroke. However, none of these techniques have yet been effectively transferred to the patient's bedside. An international group of experts has examined this issue, identifying barriers that need to be overcome for successful transferability. Among their findings, two were particularly emphasized: (i) the insufficient characterization of the mechanisms through which these stimulations are effective, and (ii) the comparison of stimulation parameters before moving on to larger samples. We have decided to use this model to study tACS (transcranial Alternating Current Stimulation) on the cerebellomotor network.

The choice of tACS is justified by (i) its ability to "entrain" a neural network through its oscillations, (ii) its innovative nature, and (iii) its "wearable" characteristic, making it quickly transferable. The choice of the cerebellomotor network is based on literature data showing that (i) the cerebellum plays a crucial role in motor learning in healthy individuals (which is one of the substrates of post-stroke recovery), and (ii) cerebellomotor synchronization is a good prognostic indicator for the recovery of hand motor function.

In light of these findings, we have decided to conduct a pathophysiological, bi-centric study to determine the cerebral mechanisms by which tACS acts on the cerebellomotor network. Three single sessions of tACS, each lasting 20 minutes, will be conducted 7-15 days apart, with a different frequency (50 or 70 Hz, corresponding to gamma oscillations) or a placebo frequency known as "sham." To understand the cerebral mechanisms, we will use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG). We will also examine a behavioral motor adaptation task on a tablet. The order in which the three frequencies are applied will be randomized This study will include 30 patients and 15 healthy subjects. The patients will be individuals who have suffered a stroke more than 6 months ago, resulting in a hand deficit without complete paralysis. The healthy controls will serve as a reference for mechanisms and imaging/electrophysiology data.

We hypothesize the following: The mechanisms involved following cerebellomotor stimulation could include a modification of brain rhythms in the beta or gamma band during movement, an increase in activity in the primary motor cortex, or a change in the excitation-inhibition balance between the cerebellum and the primary motor cortex, or directly at the level of the primary motor cortex. These different mechanisms may vary depending on the frequency used.

This research is part of the NEUROTECH Impulse Program managed by INSERM.

Eligibility

PATIENTS

Inclusion Criteria:

  • Male or female aged 18 years or older on the day of inclusion.
  • Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme.
  • Ischemic stroke or intraparenchymal hematoma that occurred more than 6 months ago, with no upper time limit.
  • Motor deficit of the upper limb confirmed by the ARAT scale, with the ability to grip and press on a tablet.
  • stroke lesion not affecting the motor cortex in the hand knob area.

Exclusion Criteria:

-- Pregnant and breastfeeding women

  • Total paralysis of the affected hand
  • Conditions that are life-threatening or could compromise follow-up during the study period
  • Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar)
  • Participation in another biomedical study focused on motor or overall recovery during the same period, or current exclusion period from another biomedical study

HEALTHY

Inclusion Criteria:

  • Male or female aged 18 years or older on the day of inclusion.
  • Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme.

Non inclusion criteria

-- Pregnant and breastfeeding women

  • Conditions that are life-threatening or could compromise follow-up during the study period
  • Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar)
  • Participation in another biomedical study during the same period, or current exclusion period from another biomedical study

Study details
    Stroke
    Healthy

NCT06599931

Institut National de la Santé Et de la Recherche Médicale, France

27 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.